Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study

Nimotuzumab is a humanized anti‐epidermal growth factor receptor IgG1 monoclonal antibody. This phase I study assessed the tolerability, safety, efficacy, and pharmacokinetics of nimotuzumab in combination with chemoradiotherapy in Japanese patients with esophageal cancer. Patients with stage II, II...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Ken, Ura, Takashi, Koizumi, Wasaburo, Iwasa, Satoru, Katada, Chikatoshi, Azuma, Mizutomo, Ishikura, Satoshi, Nakao, Yoshinori, Onuma, Hiroshi, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834813/
https://www.ncbi.nlm.nih.gov/pubmed/29285832
http://dx.doi.org/10.1111/cas.13481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834813/
https://www.ncbi.nlm.nih.gov/pubmed/29285832
http://dx.doi.org/10.1111/cas.13481

Ejemplares similares